Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second-Guessing FDA: CMS' Expanding Regulatory Role

This article was originally published in RPM Report

Executive Summary

Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.

You may also be interested in...



Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies

HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.

Orphan Drugs, 340B, and the Challenges of Implementing Health Reform

A proposed rule issued by HRSA probably changes prescription drug spending in the US by about .005%. But it will have an impact on almost every pharmaceutical company pricing department, and offers a valuable illustration of some of the bigger themes of implementing the reform law overall.

The New Part D: "Dollars for Donuts" Becomes Discounts For Data

The pharmaceutical industry's 50% donut hole discount worked out exactly as planned in the context of shaping the health care reform debate. The implementation of the new program is a different story. The program created by CMS doesn't look anything like industry would have hoped-but manufacturers have no choice but to play by CMS' rules, and try to make it work for them anyway.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel